TY - JOUR
T1 - Prostaglandins
T2 - A new class of aqueous outflow agents
AU - Toris, C. B.
AU - Camras, C. B.
PY - 1997
Y1 - 1997
N2 - The prostaglandin F(2α) analog, latanoprost, has been approved for the treatment of glaucoma in the United States. This is a new class of glaucoma agents that reduces intraocular pressure by increasing uveosclera outflow. Latanoprost is well tolerated, has few side effects, and maintains its efficacy over time. It is additive to other well established glaucoma medications, including timolol, acetazolamide, epinephrine, and pilocarpine. It has the unusual side effect of darkening the iris color in some patients with concentric heterochromia. This effect seems to be a cosmetic problem only, although further investigations are needed for confirmation.
AB - The prostaglandin F(2α) analog, latanoprost, has been approved for the treatment of glaucoma in the United States. This is a new class of glaucoma agents that reduces intraocular pressure by increasing uveosclera outflow. Latanoprost is well tolerated, has few side effects, and maintains its efficacy over time. It is additive to other well established glaucoma medications, including timolol, acetazolamide, epinephrine, and pilocarpine. It has the unusual side effect of darkening the iris color in some patients with concentric heterochromia. This effect seems to be a cosmetic problem only, although further investigations are needed for confirmation.
UR - http://www.scopus.com/inward/record.url?scp=0030880802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030880802&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:0030880802
SN - 0896-1549
VL - 10
SP - 335
EP - 355
JO - Ophthalmology Clinics of North America
JF - Ophthalmology Clinics of North America
IS - 3
ER -